Integrins in angiogenesis and lymphangiogenesis

By C. Avraamides, B. Garmy-Susini, J. Varner. Nature Reviews. Cancer, 2008

1,011 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/6af1b164b0c6b92fe9f75d5c67f7b82d17a98cfd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Hanahan
2. Zhenling Liu
3. G. Bergers
4. Huanhuan Chen
5. W. E. Hennink
6. Li-li Zheng
7. G. Storm
8. Li-Ping Sun

Citations in the corpus

• Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation (2010, background): “In particular, integrins v 3, v 5 and 5 1 are involved in angiogenesis and metastasis of solid tumors, being excellent candidates for cancer therapy [4-7].”
• To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “) and regulates the migration of the endothelial cell through the extracellular matrix during vessel formation [13].”
• Extracellular matrix: a dynamic niche component during cancer progression (2012, unknown): “Recent studies show that the ECM receptor integrin 91 plays an important role in the formation of lymphatic vessels (Huang et al., 2000; Avraamides et al., 2008), suggesting that the ECM is likely to play a role in tumor lymphangiogenesis as well.”
• Integrins in cancer: biological implications and therapeutic opportunities (2010, unknown): “The contribution of angiogenesis to tumour progression is well established and the role of integrins has recently been reviewe”
• The extracellular matrix modulates the hallmarks of cancer (2014, unknown): “The ECM surrounding the tumor acts as a reservoir for pro-and anti-angiogenic factors, provides a conduit for the migration of endothelial cells, and fosters the growth and survival of newly recruited endothelial cells [70 – 75].”
• Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release (2010, background): “Another interesting possibility of micelle-based active targeting is based on ligand-receptor interactions with angiogenesis regulators (61).”
• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “In the 1989s, Ferrara and his colleagues found a 45 kDa permeable substance through multiple layers of amino acid sequences, named vascular endothelial growth factor, a family of soluble secreted homodimeric glycoproteins.82 VEGF regulates vascular permeability, angiogenesis, and lymphogenesis.83 VE”
• Tumors as organs: complex tissues that interface with the entire organism (2010, unknown): “, 2003), is expressed in tumors and facilitates angiogenesis (Avraamides et al., 2008).”
• Modes of resistance to anti-angiogenic therapy (2008, background): “Additional reviews, in this Focus on targeting angiogenesi”
• Deletion of Cdc42 Enhances ADAM17-Mediated Vascular Endothelial Growth Factor Receptor 2 Shedding and Impairs Vascular Endothelial Cell Survival and Vasculogenesis (2013, background): “Deletion of fibronectin or integrins in ECs induces angiogenesis and vasculogenesis defects (53, 54).”